The Estronex Profile with Bone Resorption measures six important estrogen metabolites, as well as current bone loss. Assessment includes:
The “Good” Estrogen
- 2-hydroxyestrone (2-OHE1) – high levels of 2-OHE1 are ideal to reduce cancer growth.
- 2-hydroxyestradiol (2-OHE2) – shown to exhibit anti-carcinogenic effects.
- 2-methoxyestrone (2-OMeE1) – OMeE1 has shown to have anticancer effects and is ideal in high levels.
- 4-methoxyestrone (4-OMeE1) – as a non-cancerous metabolite, OMeE1 generally does not require treatment at high levels in the body.
The “Bad” Estrogen
- 4-hydroxyestrone (4-OHE1) – considered a “bad” estrogen, 4-OHE1 levels should be low, as high levels may react negatively with damaged DNA.
- 16-α-hydroxyestrone (16α-OHE1) – also considered a “bad” estrogen, 16α-OHE1 in high levels may encourage tumor development.
- 2-OHE:16α-OHE1 (2:16 ratio) – 2:16 ratios less than 2.0 indicate increasing long-term risk for breast, cervical, and other estrogen sensitive cancers. Importantly, nutritional interventions can help raise Estronex 2:16 ratios and decrease long-term risk. Studies also indicate that this risk is modifiable!
- 2-OHE1:2-OMeE1 – a high level of 2-OHE1:2-OMeE1 may also indicate imbalanced estrogen metabolism and low activity in the COMT gene. Evaluation of methylation activity is recommended.
Deoxypyridinoline – a fragment of Type I collagen breakdown that contains the cross-linking point and has been demonstrated to be more specific to bone resorption than breakdown fragments measured in some earlier assays.
- UPLC Tandem Mass Spectrometry